Servier Stumbles in Muscle Disease as Drug From $1.5B Deal Fails Pivotal Test
Servier’s sevasemten came from the acquisition of the muscular dystrophy assets of Edgewise Therapeutics. While the small molecule had met the goal of a Phase 2 test in Becker muscular dystrophy, Servier said new results in a pivotal cohort do not show statistically significant benefit.
When Patients Become Consumers: The New Care Stack Collides With Legacy Healthcare
To succeed, our healthcare system must fully embrace consumer-focused product design to address demands of scale, access, and daily usability that the market is revealing.
Breast Cancer Survivorship Is a Menopause Problem Nobody Owns
For all the pink ribbons we see, women with breast cancer are abandoning one of the most effective treatments they have because of symptoms no one in their care team is clearly responsible for.
The FTC Is Flexing Its Muscle in Healthcare
The FTC sent warning letters to 25 health plan marketers over potentially deceptive marketing practices, following its earlier letters to healthcare services companies about price transparency.
Flagship Merges 3 Startups to Turn Cause and Effect Insights Into Novel Medicines
Flagship Pioneering unveiled Etcelera, a new startup formed by combining three of the firm’s portfolio companies. Etcelera's approach to drug R&D focuses on “causal intelligence,” which Flagship defines as predicting and understanding cause and effect in biology.